Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Dosing commences in phase IIIb study of rhIGF-1 for primary IGF-1 deficiency

Nov. 3, 2004

Aastrom signs diabetic limb ischemia trial agreement

Nov. 3, 2004

Takeda submits Actoplus Met NDA for type 2 diabetes

Nov. 3, 2004

New vitamin D analogues and their use in bone diseases, cancer, etc.

Nov. 3, 2004

Mimpara approved in Europe

Nov. 2, 2004

Bile acid transport inhibitors may lower plasma cholesterol levels

Nov. 2, 2004

New melanocortin MC4 agonists under study at Merck

Nov. 2, 2004

Short-term efficacy of a combination of JTT-705 plus pravastatin in type II dyslipidemia

Oct. 29, 2004

Rimonabant reported to improve insulin response in obese patients with dyslipidemia

Oct. 29, 2004

Novo Nordisk terminates development of balaglitazone

Oct. 29, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...